Price Momentum and Recent Performance
The stock closed at ₹850.10 on 16 Jul 2026, marking a 3.54% increase from the previous close of ₹821.00. Intraday, it traded between ₹818.95 and ₹853.70, showing resilience near its short-term highs. Despite this uptick, Alembic remains below its 52-week high of ₹1,064.70, while comfortably above the 52-week low of ₹635.30.
Comparatively, Alembic outperformed the Sensex over the past week and month, with returns of 4.81% and 15.10% respectively, against the Sensex’s 0.89% and 1.21%. However, on a year-to-date basis, the stock’s return is a marginal 0.22%, outperforming the Sensex’s negative 9.43%. Over one year, Alembic has declined 17.60%, underperforming the Sensex’s 6.52% loss, while its three-year return of 29.33% surpasses the Sensex’s 16.84%. Longer-term, the five-year and ten-year returns lag the benchmark, indicating mixed performance over extended periods.
Technical Trend Shift: From Mildly Bearish to Sideways
The technical trend for Alembic Pharmaceuticals has shifted from mildly bearish to sideways, signalling a pause in the previous downtrend. This suggests that the stock may be consolidating before a potential directional move. The daily moving averages remain mildly bearish, indicating that short-term momentum is still under pressure, but the weekly and monthly indicators present a more nuanced picture.
On the weekly chart, the Moving Average Convergence Divergence (MACD) is bullish, reflecting increasing upward momentum. Conversely, the monthly MACD remains bearish, highlighting longer-term caution. The Relative Strength Index (RSI) on both weekly and monthly timeframes shows no clear signal, hovering in neutral zones that neither indicate overbought nor oversold conditions.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Bollinger Bands and Moving Averages Analysis
Bollinger Bands on the weekly timeframe are bullish, indicating that price volatility is expanding upwards and the stock is trading near the upper band, a sign of strength. However, the monthly Bollinger Bands are mildly bearish, suggesting that longer-term volatility remains subdued with a slight downward bias.
Daily moving averages continue to show a mildly bearish stance, with the stock price hovering close to or slightly below key averages such as the 50-day and 200-day moving averages. This indicates that while short-term momentum is fragile, the sideways trend could be a precursor to a breakout or breakdown depending on upcoming market catalysts.
Additional Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator presents a bullish signal on the weekly chart but remains bearish on the monthly, reinforcing the mixed momentum across different timeframes. Dow Theory assessments are mildly bullish on both weekly and monthly scales, suggesting that the broader trend may be stabilising with potential for upward movement.
On-Balance Volume (OBV) readings are bullish on both weekly and monthly charts, indicating that volume trends support the recent price gains. This volume confirmation is a positive sign, as it suggests accumulation by investors despite the mixed technical backdrop.
Mojo Score and Rating Upgrade
Alembic Pharmaceuticals currently holds a Mojo Score of 51.0, which corresponds to a Hold rating. This is an upgrade from the previous Sell rating, effective from 15 Jul 2026. The upgrade reflects improved technical and fundamental assessments, though the stock remains classified as a small-cap within the Pharmaceuticals & Biotechnology sector. Investors should note that while the rating has improved, the overall outlook remains cautious given the mixed signals from key technical indicators.
Investment Implications and Outlook
The recent technical parameter changes for Alembic Pharmaceuticals suggest a stock in transition. The shift from a mildly bearish trend to sideways momentum, combined with bullish weekly MACD and OBV signals, points to a potential stabilisation phase. However, the bearish monthly MACD and mildly bearish daily moving averages counsel prudence.
Investors should monitor key support and resistance levels, particularly the 52-week high of ₹1,064.70 and the recent lows near ₹635.30. A sustained move above the daily moving averages and confirmation from monthly indicators could signal a more definitive uptrend. Conversely, failure to hold current levels may lead to renewed selling pressure.
Given the stock’s mixed performance relative to the Sensex and its small-cap status, Alembic Pharmaceuticals may appeal to investors with a medium-term horizon who are comfortable navigating technical volatility within the Pharmaceuticals & Biotechnology sector.
Considering Alembic Pharmaceuticals Ltd.? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Conclusion
Alembic Pharmaceuticals Ltd. is currently navigating a complex technical landscape marked by a shift to sideways momentum and a blend of bullish and bearish signals across multiple indicators. The recent upgrade to a Hold rating and improved Mojo Score reflect a cautiously optimistic stance, but investors should remain vigilant for confirmation of trend direction.
With weekly indicators suggesting potential strength and monthly signals urging caution, the stock’s near-term trajectory will likely depend on broader market conditions and sector-specific developments. For those considering exposure to this small-cap pharmaceutical player, a balanced approach with close attention to technical levels and volume trends is advisable.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
